RASBURICASE Side Effects

7001510-3 | Disease Progression
on Sep 16, 2010 Female patient from JAPAN , 16 years of age, weighting 143.3 lb, was diagnosed with hyperuricaemia and was treated with Rasburicase (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression. Rasburicase dosage: .

6933869-7 | Hepatotoxicity
Patient was taking Rasburicase (View Usage). Patient had the following side effects: hepatotoxicity on Aug 09, 2010 from SPAIN Additional patient health information: Male patient , 38 years of age, was diagnosed with b-cell lymphoma stage iv, hyperlipidaemia and. Rasburicase dosage: . During the same period patient was treated with METOTREXATO (View Metotrexato Review and Metotrexato Label ), ATORVASTATIN (View Atorvastatin Review and Atorvastatin Label ), CITARABINA (View Citarabina Review and Citarabina Label ), MABTHERA (View Mabthera Review and Mabthera Label ).

4903714-X | Alanine Aminotransferase Increased, Anti-hbs Antibody Positive, Aspartate Aminotransferase Increased, Blood Lactate Dehydrogenase Increased, Confusional State, Cough, Dyspnoea, Liver Function Test Abnormal, Muscle Twitching
Adverse event was reported on Jan 21, 2005 by a Male patient taking Rasburicase (View Usage) (Dosage: ) was diagnosed with hyperuricaemia and. Location: UNITED STATES , weighting 207.2 lb, After Rasburicase was administered, patient had the following side effects: alanine aminotransferase increased, anti-hbs antibody positive, aspartate aminotransferase increased, blood lactate dehydrogenase increased, confusional state, cough, dyspnoea, liver function test abnormal, muscle twitching. During the same period patient was treated with ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), CYTARABINE (Unk) (View Cytarabine Review and Cytarabine Label ), MITOXANTRONE (Unk) (View Mitoxantrone Review and Mitoxantrone Label ), ZOSYN (Unk) (View Zosyn Review and Zosyn Label ), GENTAMICIN (Unk) (View Gentamicin Review and Gentamicin Label ), FORTAZ (Unk) (View Fortaz Review and Fortaz Label ), VANCOMYCIN (Unk) (View Vancomycin Review and Vancomycin Label ), ACYCLOVIR (Unk) (View Acyclovir Review and Acyclovir Label ).

4835468-X | Blood Pressure Decreased, Feeling Hot, Infusion Related Reaction, Oxygen Saturation Decreased, Syncope
on Nov 22, 2005 Male patient from UNITED STATES , weighting 416.2 lb, was diagnosed with hyperuricaemia, stem cell transplant and was treated with Rasburicase (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure decreased, feeling hot, infusion related reaction, oxygen saturation decreased, syncope. Rasburicase dosage: 15 Mg Iv X 1 Dose. During the same period patient was treated with LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), VALACYCLOVIR HCL (View Valacyclovir Hcl Review and Valacyclovir Hcl Label ), PANTOPRAZOLE (View Pantoprazole Review and Pantoprazole Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), SERTRALINE HCL (View Sertraline Hcl Review and Sertraline Hcl Label ), METOLAZONE (View Metolazone Review and Metolazone Label ).


4640183-1 | Blood Potassium Decreased, Bronchospasm, Chills, Dyspnoea, Haemoglobin Decreased, Hyperthermia, Hypotension
on Apr 14, 2003 Female patient from , 57 years of age, was diagnosed with hyperuricaemia, non-hodgkin's lymphoma and was treated with Rasburicase (View Usage). Patient had the following side effects: blood potassium decreased, bronchospasm, chills, dyspnoea, haemoglobin decreased, hyperthermia, hypotension. Rasburicase dosage: 10.5 Mg Intravenous Nos. During the same period patient was treated with LYSANXIA 10 (PRAZEPAM) (View Lysanxia 10 (prazepam) Review and Lysanxia 10 (prazepam) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

4639249-1 | Cardiac Arrest, Gallbladder Disorder, Gastrointestinal Haemorrhage, Haematuria, Hepatic Failure, Hepatitis B, Hepatotoxicity, Platelet Count Decreased, Pulmonary Haemorrhage
Patient was taking Rasburicase (View Usage). After Rasburicase was administered, patient had the following side effects: cardiac arrest (What is cardiac arrest?), gallbladder disorder, gastrointestinal haemorrhage, haematuria, hepatic failure, hepatitis b (What is hepatitis b?), hepatotoxicity, platelet count decreased, pulmonary haemorrhage on Oct 29, 2004 from Additional patient health information: Female patient , weighting 126.3 lb, was diagnosed with hyperuricaemia and. Rasburicase dosage: . During the same period patient was treated with ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), VANCOMYCIN (Unk) (View Vancomycin Review and Vancomycin Label ), FORTAZ (Unk) (View Fortaz Review and Fortaz Label ), NAFCILLIN SODIUM (Unk) (View Nafcillin Sodium Review and Nafcillin Sodium Label ), ACYCLOVIR (Unk) (View Acyclovir Review and Acyclovir Label ), SPORANOX (Unk) (View Sporanox Review and Sporanox Label ), CIPROFLOXACIN (Unk) (View Ciprofloxacin Review and Ciprofloxacin Label ), G CSF (Unk) (View G-csf Review and G-csf Label ).

4624808-2 | Bronchospasm, Chills, Dyspnoea, Hyperthermia, Hypotension
Adverse event was reported on Apr 14, 2003 by a Female patient taking Rasburicase (View Usage) (Dosage: 10.5 Mg) . Location: , weighting 121.3 lb, Patient experienced the following unwanted or unexpected effects: bronchospasm, chills, dyspnoea, hyperthermia, hypotension. During the same period patient was treated with LYSANXIA 10 (Unk) (View Lysanxia 10 Review and Lysanxia 10 Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

4619117-1 | Bronchospasm, Dyspnoea, Hyperthermia, Hypotension
on Apr 14, 2003 Female patient from , weighting 121.3 lb, was treated with Rasburicase (View Usage). Patient had the following side effects: bronchospasm, dyspnoea, hyperthermia, hypotension. Rasburicase dosage: 10.5 Mg. During the same period patient was treated with LYSANXIA 10 (Unk) (View Lysanxia 10 Review and Lysanxia 10 Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

4565649-4 | Blood Creatinine Increased, Dyspnoea, Methaemoglobinaemia, Oxygen Saturation Decreased, Po2 Increased, Tumour Lysis Syndrome
on Jan 25, 2005 Male patient from , 58 years of age, weighting 229.3 lb, was diagnosed with blood uric acid increased, prophylaxis, tumour lysis syndrome and was treated with Rasburicase (View Usage). After Rasburicase was administered, patient had the following side effects: blood creatinine increased, dyspnoea, methaemoglobinaemia, oxygen saturation decreased, po2 increased, tumour lysis syndrome. Rasburicase dosage: 15mg Q Day Intravenous. During the same period patient was treated with DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), DOCUSATE (View Docusate Review and Docusate Label ).